Sprout Health Review 2026

Overview

Sprout Health is a telehealth service offering compounded semaglutide from $149/month and compounded tirzepatide from $199/month, with brand-name Wegovy and Zepbound also available at cash prices, plus a separate compounded NAD+ line. What distinguishes it is not the pricing, which is competitive but not exceptional, but the quality of its disclosure — which is the best we have encountered across this entire directory. Where most competitors bury a one-line FDA caveat in a footer or omit it, Sprout states in the body of its weight-loss page that 'Compounded semaglutide and tirzepatide are not approved by the FDA and have not been evaluated for safety, effectiveness, or quality by the FDA' and then adds the sentence almost nobody else includes: 'Compounded drugs are not brand name drugs nor are they considered to be generics.' That second clause closes the exact misconception the FDA cited 30 telehealth companies over in March 2026. It goes further on commercial terms too, stating that plans renew automatically and that billing frequency and how to cancel are shown before checkout, alongside 'No contracts, no surprise fees'. In a market where auto-renewal and cancellation cutoffs are routinely hidden until after payment, disclosing them pre-checkout is genuinely unusual. The gaps are in clinical specifics rather than commercial ones: no published BMI threshold, eligibility criteria, lab requirements or state list, and almost no independent review record to test any of it against.

Medications Offered

Brand-name or compounded: Both — compounded semaglutide and tirzepatide (not FDA-approved) plus brand-name Wegovy and Zepbound at cash prices.

• Compounded semaglutide — starting at $149/month
• Compounded tirzepatide — starting at $199/month
• Compounded GLP-1 and GIP/GLP-1 tier — starting at $249/month
• Brand-name Wegovy® — starting at $1,799/month
• Brand-name Zepbound® — starting at $1,999/month
• Compounded NAD+ therapy — sold as a separate longevity line

Consultation Process

Eligibility

• Adults; no published BMI threshold or age range
• Provider review of a medical history form required
• Prescription issued only 'if deemed necessary and appropriate by your medical provider'
• No insurance required — cash-pay
• State availability is not published

Provider Involvement

Sprout states its providers are state-licensed and that prescriptions are filled by state-licensed pharmacies, with a patient care team available for support. The prescribing pathway is form-based rather than appointment-based, and no lab requirement or monitoring cadence is published. It is honest about its own role — 'Sprout is not a pharmacy or drug manufacturer' — which matters given the FDA's finding against another provider in this directory for implying exactly that relationship.

Lab Requirements

Not published. Ask what baseline and ongoing monitoring is expected before starting.

Pharmacy Fulfillment

Medication is 'prepared by state-licensed US pharmacies' and Sprout states it is not itself a pharmacy or manufacturer. Individual facilities are not named. The disclosure that compounded drugs are neither brand-name nor generic is unusually precise and to the company's credit; naming the pharmacies would complete the picture.

Shipping Frequency

Prescriptions reach the pharmacy within two business days of the completed medical form; onward delivery timing is not published.

Membership Fees vs. Medication Fees

Cancellation & Refund Policy

Insurance

No insurance route is advertised, and this explains the brand-name pricing. Wegovy at $1,799/month and Zepbound at $1,999/month are approximately full cash list prices — these are not discounted rates, and buying brand-name product this way is far more expensive than obtaining it on a pharmacy benefit. If you have coverage, use a provider that bills it.

HSA / FSA

Not stated. Confirm directly.

See our GLP-1 insurance and HSA/FSA guide for how reimbursement works in practice.

Support Services

• Patient care team described as 'real people, real answers'
• 100% online process with no waiting rooms
• Billing frequency and cancellation method disclosed pre-checkout
• Discreet delivery

State Availability

Not published. No state list or exclusions appear on the pages we reviewed.

Pros

• The clearest compounding disclosure we have found anywhere in this directory
• States explicitly that compounded drugs are 'not brand name drugs nor are they considered to be generics'
• Publishes billing frequency and cancellation method before checkout, by its own account
• Compounded semaglutide from $149/month and tirzepatide from $199/month
• Brand-name Wegovy and Zepbound offered alongside compounded options
• 'No contracts, no surprise fees' — no minimum term advertised
• Prescriptions sent to the pharmacy within two business days of the medical form

Cons

• Brand-name pricing is full cash list — Wegovy from $1,799/month and Zepbound from $1,999/month
• A third compounded GLP-1/GIP tier at $249/month sits above the headline rates without a clear explanation
• Also markets compounded NAD+, which has no established evidence for the benefits implied
• No published eligibility criteria, BMI threshold, lab requirements or state list
• Very little independent review record to test the on-site claims against
• No refund policy published

Who Sprout Health May Be Best For

• Buyers who want the regulatory position spelled out rather than buried
• People who want no minimum commitment and clear pre-checkout billing terms
• Patients choosing between compounded and brand-name on the same platform

Limitations

• Brand-name pricing is full cash list and very expensive
• No eligibility criteria, BMI threshold, labs or state list published
• No refund policy published
• Minimal independent review record
• Compounded NAD+ marketed on unevidenced longevity claims

Reputation & Trust

Sprout's disclosure quality is the story here, and it is genuinely best-in-class for this directory. It states that compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated for safety, effectiveness or quality; that compounded drugs are neither brand-name drugs nor generics; that it is not itself a pharmacy or manufacturer; that plans renew automatically; and that billing frequency and cancellation method are shown before checkout. Each of those is a sentence a less scrupulous operator would omit, and together they address most of the specific failure modes documented elsewhere in this directory — the implied-equivalence claims that drew FDA warning letters, the hidden auto-renewal that generates billing complaints, and the compounder-identity confusion the FDA cited MEDVi over. What we cannot offer is corroboration: there is very little independent review record for Sprout Health, so the assessment rests on its own published material rather than on customer outcomes. The compounded NAD+ line is also sold on the usual unevidenced longevity framing, which sits oddly against the rigour of the GLP-1 disclosures.

What Makes Sprout Health Different

• Explicitly states compounded drugs are neither brand-name nor generic — a distinction almost nobody publishes
• Auto-renewal and cancellation method disclosed before checkout rather than after
• Both compounded and brand-name routes on one platform
• States plainly that it is not a pharmacy or drug manufacturer
• No contracts or minimum term advertised

Our Verdict

Alternatives to Sprout Health

Compare more options on our best online GLP-1 providers and cheapest GLP-1 programs pages.

Frequently Asked Questions

Important Notes & Warnings

Sources

• Sprout Health weight-loss and NAD+ pages, joinsprouthealth.com (accessed 7 August 2026)
• FDA press announcement, 'FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s', 3 March 2026, for context on the disclosure standard